Perigon Wealth Management LLC Takes Position in Entera Bio Ltd. (NASDAQ:ENTX)

Perigon Wealth Management LLC acquired a new position in shares of Entera Bio Ltd. (NASDAQ:ENTX - Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 145,843 shares of the company's stock, valued at approximately $325,000. Perigon Wealth Management LLC owned about 0.41% of Entera Bio at the end of the most recent reporting period.

Separately, Parkman Healthcare Partners LLC increased its position in shares of Entera Bio by 2.4% during the third quarter. Parkman Healthcare Partners LLC now owns 411,076 shares of the company's stock worth $781,000 after purchasing an additional 9,558 shares in the last quarter. 14.11% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Entera Bio in a research report on Monday, November 11th.

Entera Bio Trading Up 5.0 %

Shares of ENTX stock traded up $0.12 during trading hours on Thursday, reaching $2.52. 220,410 shares of the company's stock were exchanged, compared to its average volume of 216,255. The stock has a market cap of $90.17 million, a PE ratio of -9.69 and a beta of 1.52. The stock's fifty day moving average price is $2.23 and its two-hundred day moving average price is $1.93. Entera Bio Ltd. has a 1 year low of $0.71 and a 1 year high of $3.35.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.